Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

More News! 14 Dec 2017

New Biotech in Oxford Takes on Arthritis of the Spine

Izana Bioscience has been launched today to develop an antibody to treat ankylosing spondylitis, a form of arthritis that affects the spine. Oxford’s newest biotech, Izana Bioscience, has an exclusive license from Takeda to develop the antibody drug Namilumab (IZN-101) and a £1.35M grant from Innovate UK to fund a Phase II study. The company plans to […]

December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 14 Dec 2017

10 Biotechnology Books To Read These Winter Holidays

Here is a list of some of the best biotechnology books to add to your 2018 to-read list and get up to date with the ins and outs of the biotech world. Winter is here, at least for those of us living in the Northern hemisphere. I am personally looking forward to warm evenings at […]

December 14, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Dec 2017

Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment

Data presented at ASH 2017 shows that Servier and Pfizer’s UCART19, an allogeneic CAR-T therapy originally developed by Cellectis, might struggle to outperform autologous CAR-T cells. CAR-T cell therapy has proved to be effective at treating cancer in patients for whom scarce hope was left. Yet pricing is still a big concern. Companies like Cellectis are trying […]

December 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

CRISPR Therapeutics clinical trials CRISPR Cas9

News and Trends 13 Dec 2017

CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018

CRISPR Therapeutics and Vertex Pharmaceuticals are taking action to start a first clinical trial with CRISPR/Cas9 in Europe in 2018. The blood disorder β-thalassemia could soon be the first human disease to be treated using CRISPR/Cas9 technology in Europe. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have announced the first candidate from their collaboration that will go […]

December 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2017

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100 available to patients with uveal melanoma before approval. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has deemed Immunocore’s technology worth being used by patients before it’s approved. The regulatory agency has granted Promising Innovative Medicines (PIM) designation to IMCgp100 for […]

December 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2017

New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH

NorthSea Therapeutics has been founded in the Netherlands to develop a drug against NASH, a disease with no treatment and a huge market. With a €25M investment in Series A, NorthSea Therapeutics is all set to start Phase II trials in nonalcoholic steatohepatitis (NASH) and take on a very profitable market. The fundraising was led by Forbion […]

December 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Dec 2017

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

A Phase II proof of concept study has shown that one of Argenx’ antibodies is effective in treating the neuromuscular disease myasthenia gravis. Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease […]

December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 11 Dec 2017

Edwin Moses on how Ablynx has made it to the top of European biotech

Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the biggest European biotechs. Ablynx, based in Belgium, has just recently joined the European billion-euro biotech club with a market cap of €1.45Bn. With positive Phase III results for its lead compound and a $230M (€195M) […]

December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

wilsons disease treatment wilson therapeutics sweden 1

News and Trends 8 Dec 2017

Wilson’s Disease Treatment Gets a €24.4M Equity Boost in Sweden

Wilson Therapeutics has issued new shares on Nasdaq Stockholm, raising a total of SEK 244M (€24.4M) to help bring its Wilson’s disease treatment to the market. Stockholm-based biotech Wilson Therapeutics has closed a share issue that seems to have generated quite a high demand. The company’s main shareholders, Abingworth and MVM, had to sell SEK 156.75M […]

December 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Dec 2017

A London Biotech Aims to Overtake the Dry Eye Syndrome Market

TopiVert has released the results of a clinical trial that the company believes yielded “the best proof of concept data in dry eye syndrome.” Based in London, the biotech company TopiVert is trying to enter the $3Bn market of dry eye syndrome with a drug with the potential to work better than the options currently […]

December 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Dec 2017

Scottish Biotech and Bluebird Bio to Develop Next Generation CAR-T Cells

TC Biopharm has scored a deal with bluebird bio for the development of the next generation of CAR-T cells, a technology giving new hope to cancer patients. With the first two CAR-T therapies now in the market, the way we treat cancer is changing. This technology has shown to be effective in a high percentage of patients […]

December 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

advicenne ipo rare disease children drta

News and Trends 6 Dec 2017

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

Update (6/12/2017): Advicenne has raised a total of €27M on Euronext Paris, putting its market cap at €112M. Originally published on 21/11/2017 Advicenne is launching an IPO on Euronext Paris to raise the funds to bring the first treatment for dRTA, a rare disease of the kidneys, to the market. Advicenne, based in Nîmes, France, has officially […]

December 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

New Biotech in Oxford Takes on Arthritis of the Spine

10 Biotechnology Books To Read These Winter Holidays

Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment

CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

Edwin Moses on how Ablynx has made it to the top of European biotech

Wilson’s Disease Treatment Gets a €24.4M Equity Boost in Sweden

A London Biotech Aims to Overtake the Dry Eye Syndrome Market

Scottish Biotech and Bluebird Bio to Develop Next Generation CAR-T Cells

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!